Healthcare / BiotechnologyNasdaqGS
$0.68
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-56.4M · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
4/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$33M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-245.2%
↓Gross Margin
N/A
•Debt/Equity
1.29
↑Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-60.8M · FCF $-60.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-60.8M | $-60.8M | $-70.5M | $-37.4M | $-53.8M | $-50.0M | $-15.0M |
| EPS | -1.33 | -1.33 | -1.63 | -1.05 | -1.86 | -10.94 | -28.08 |
| Balance Sheet | |||||||
| Debt/Equity | 1.29 | 1.29 | 0.44 | 0.36 | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-60.3M | $-60.3M | $-56.4M | $-33.4M | $-44.2M | $-43.4M | $-19.2M |
| Returns | |||||||
| ROE | -245.2% | -245.2% | -96.1% | -33.6% | -44.0% | -32.7% | 29.0% |
| Growth & Yield | |||||||
| EPS Growth | 18.4% | 18.4% | -55.2% | 43.5% | 83.0% | 61.0% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.